Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 1
2006 3
2008 1
2009 2
2010 3
2011 2
2012 4
2013 7
2014 6
2015 3
2016 6
2017 4
2018 5
2019 9
2020 12
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Pregnancy and Family Planning in Multiple Sclerosis.
Langer-Gould AM. Langer-Gould AM. Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi: 10.1212/CON.0000000000000745. Continuum (Minneap Minn). 2019. PMID: 31162316 Review.
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. Among authors: langer gould a. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.
Environmental and genetic risk factors for MS: an integrated review.
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A. Waubant E, et al. Among authors: langer gould a. Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922. doi: 10.1002/acn3.50862. Epub 2019 Aug 7. Ann Clin Transl Neurol. 2019. PMID: 31392849 Free PMC article. Review.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. Hauser SL, et al. Among authors: langer gould a. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383. N Engl J Med. 2008. PMID: 18272891 Free article. Clinical Trial.
Rituximab, MS, and pregnancy.
Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Smith JB, et al. Among authors: langer gould a. Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4):e734. doi: 10.1212/NXI.0000000000000734. Print 2020 Jul. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32358226 Free PMC article.
The prevalence of MS in the United States: A population-based estimate using health claims data.
Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup. Wallin MT, et al. Among authors: langer gould a. Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Neurology. 2019. PMID: 30770430 Free PMC article.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Alping P, et al. Among authors: langer gould a. Ann Neurol. 2020 May;87(5):688-699. doi: 10.1002/ana.25701. Epub 2020 Mar 9. Ann Neurol. 2020. PMID: 32056253 Free article.
75 results